The evidence-base for palliative care within a stroke context is limited: recommendations focus exclusively on end of life, and draw mostly on research completed in cancer populations. These may only partly be transferable to a stroke context. This paper addresses this gap by investigating the integration of palliative care into the acute stroke pathway. Dealing with palliative care and end of life issues places considerable demands on the resilience of patients and family members. The role of health services is to provide appropriate and effective support helping
patients and families to cope with, and adapt to these demands, although performance may be problematic . Information provision, communication Inhibitors,research,lifescience,medical and decision-making within a multi-disciplinary team context, Inhibitors,research,lifescience,medical and in partnership with patients and family to determine preferences for care are key . As with comparable health care systems, health policy in UK end-of-life care highlights the importance of developing generalist palliative care expertise outside of cancer services. Enabling patient choice about where Inhibitors,research,lifescience,medical care is delivered is expected to lead to a greater proportion of people dying at home rather than in hospital . The conceptual basis for palliative care outlined by the World Health
Organisation (WHO)  is broader than end of life care, and stresses implementation earlier in the disease trajectory in conjunction with other therapies intended to minimise disease progression and prolong life. It is now widely recognised that palliative care Inhibitors,research,lifescience,medical has a crucial role in the care received by patients and carers throughout the course of a disease process. Its supportive nature is intended to help the patient to maximise the benefits of treatment and to live as well as possible with the effects of the disease . In practice, acute stroke services will be increasingly Inhibitors,research,lifescience,medical required to attend to palliative and end of life issues. Significant
advances have been made in the implementation of evidence of the effectiveness of rapid neurological assessment, specialist management and organised service design for people affected by stroke. GSK-3 The stroke service model has shifted from one that Oligomycin A clinical trial reflects a sense of therapeutic nihilism, historically located within gerontological medicine, to one that reflects neurological urgency and optimism. Although public health initiatives and lifestyle changes may explain a general downward trend in stroke incidence , the development of thrombolytic inhibitor therapy for acute stroke, effective secondary prevention strategies, and organised specialist services that integrate early rehabilitation [12,13] reduce the impact of stroke for patients, families and society. Clinical guidelines and health policy indicate that all stroke patients should be given the opportunity to benefit from acute stroke services.